Estimated Effects of Amyloid Reduction on Cognitive Change: A Bayesian Update across a Range of Priors
Preprint
Abstract
Introduction Results of the CLARITY-AD and GRADUATE I and II trials rekindled discussion on the impact of amyloid-targeting drugs. We use a Bayesian approach to quantify how a rational observer would have updated their prior beliefs based on new trial results. Methods We used publicly available data from the CLARITY-AD and GRADUATE I & II trials to estimate the effect of reducing amyloid on CDR-SB score. A range of prior positions were then updated according to Bayes Theorem using these estimates. Results After updating with new trial data, a wide range of starting positions resulted in credible intervals that did not include no effect of amyloid reduction on CDR-SB. Discussion For a range of starting beliefs and assuming veracity of underlying data, rational observers would conclude there is a small benefit of amyloid-reductions on cognition. This benefit must be weighed against opportunity cost and side effect risk.Keywords
All Related Versions
- Published version: Alzheimer's & Dementia, 20 (2), 1149.
This publication has 30 references indexed in Scilit:
- Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an updated instrumental variable meta-analysismedRxiv, 2022
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsNature Reviews Drug Discovery, 2022
- Cognitive outcomes of anti‐amyloid‐β monoclonal antibodies in patients with Alzheimer's disease: A systematic review and meta‐analysis of randomized controlled trialsAlzheimer's & Dementia, 2021
- What the Aducanumab Approval Reveals About Alzheimer Disease ResearchJAMA Neurology, 2021
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s diseaseAgeing Research Reviews, 2021
- Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?Expert Review of Neurotherapeutics, 2019
- Accuracy and the Laws of Credence2016
- Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scoresAlzheimer's & Dementia, 2012
- The Foundations of Decision under Uncertainty: An Elementary ExpositionJournal of the American Statistical Association, 1964